MR Based Survival Prediction of Glioma Patients Using Artificial Intelligence

NCT04215211 · tracked via the Priya Life Science China tracker

Sponsor

The First Affiliated Hospital of Zhengzhou University

Phase

Observational

Started

2017-01-01

Last updated

2021-02-08

Condition(s) studied

Glioma

Investigational drug(s) / intervention(s)

Survival prediction for glioma patients

Survival prediction for glioma patients: Survival prediction of glioma patients in the frame of molecular pathology by leveraging AI

Study summary

This registry aims to collect clinical, molecular and radiologic data including detailed survival data, clinical parameters, molecular pathology (1p/19q codeletion, MGMT methylation, IDH and TERTp mutations, etc) and conventional/advanced/new MR sequences (T1, T1c, T2, FLAIR, ADC, DTI, PWI, etc) of patients with primary gliomas. By leveraging artificial intelligence, this registry will seek to construct and refine algorithms that able to predict patients' survivals in the frame of molecular pathology or subgroups of gliomas.

Eligibility

Sex

ALL

Min age

1 Year

Max age

90 Years

Healthy volunteers

Inclusion Criteria: * Patients must have radiologically and histologically confirmed diagnosis of primary glioma * Life expectancy of greater than 3 months * Must receive tumor resection * Signed informed consent Exclusion Criteria: * No gliomas * No sufficient amount of tumor tissues for detection of molecular pathology * Patients who have any type of bioimplant activated by mechanical, electronic, or magnetic devices * Patients who are pregnant or breast feeding * Patients who are suffered from severe systematic malfuctions

Primary outcome measure(s)

AUC of survival prediction performance — up to 10 years
AUC of survival prediction performance=sensitivity+specificity-1

Trial sites (1)

Facility	City	Region	Status
Department of Neurosurgery, First Affiliated Hospital of Zhengzhou University	Zhengzhou	Henan	Recruiting

More The First Affiliated Hospital of Zhengzhou University trials in China

Clinical Outcomes of Drug-Coated Balloons in the Treatment of Patients With Coronary De Novo Chronic Total Occlusion Lesions Recruiting

Tenecteplase for Late-Window Stroke Guided by DWI-FLAIR Mismatch Starting soon

A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALL Recruiting

Retlirafusp Alfa Combined With Famitinib, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic Cancer Starting soon

Pro-urokinase for Extended-Window Posterior Circulation Stroke Starting soon

Other trials for the same condition

Sub-lobectomy for IDH Wild-type and TERT Promoter Mutant Glioblastoma Starting soon

Prospective Real-World Study of Pathology AI for Glioma Molecular Prediction Recruiting

Histopathology Images Based Prediction of Molecular Pathology in Glioma Using Artificial Intelligence Recruiting

Effect of Electroacupuncture Combined With Paclitaxel Clinical Efficacy of Patients With Recurrence of High-grade Glioma Recruiting

The Role of B7-H4 in Tumor Vaccine Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04215211 on ClinicalTrials.gov ↗ ← All trials in China